• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Longitude Capital Partners Ii, Llc exercised 629,032 in-the-money shares at a strike of $0.05 and sold $473,859 worth of shares (108,739 units at $4.36) (SEC Form 4)

    2/3/26 8:50:11 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RPID alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Longitude Capital Partners II, LLC

    (Last) (First) (Middle)
    C/O LONGITUDE CAPITAL MANAGEMENT
    2740 SAND HILL ROAD, 2ND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    RAPID MICRO BIOSYSTEMS, INC. [ RPID ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/23/2026
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 01/23/2026 X(1) 629,032 A $0.05 4,036,984 I Held by Longitude Venture Partners II, L.P.(2)
    Class A Common Stock 01/23/2026 S(1) 7,739 D $4.064 4,029,245 I Held by Longitude Venture Partners II, L.P.(2)
    Class A Common Stock 01/30/2026 S 46,000 D $4.5435 104,000 I Held by Longitude Prime Fund, L.P.(3)
    Class A Common Stock 02/02/2026 S 27,500 D $4.246 76,500 I Held by Longitude Prime Fund, L.P.(3)
    Class A Common Stock 02/03/2026 S 27,500 D $4.2415 49,000 I Held by Longitude Prime Fund, L.P.(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Class A Common Stock $0.05 01/23/2026 X 500,000 (4) 07/24/2027 Class A Common Stock 500,000 $0 0 I Held by Longitude Venture Partners II, L.P.(2)
    Class A Common Stock $0.05 01/23/2026 X 129,032 (4) 01/17/2028 Class A Common Stock 129,032 $0 0 I Held by Longitude Venture Partners II, L.P.(2)
    1. Name and Address of Reporting Person*
    Longitude Capital Partners II, LLC

    (Last) (First) (Middle)
    C/O LONGITUDE CAPITAL MANAGEMENT
    2740 SAND HILL ROAD, 2ND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Longitude Venture Partners II, L.P.

    (Last) (First) (Middle)
    2740 SAND HILL ROAD, SECOND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Longitude Prime Partners, LLC

    (Last) (First) (Middle)
    2740 SAND HILL ROAD, SECOND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    ENRIGHT PATRICK G

    (Last) (First) (Middle)
    2740 SAND HILL ROAD, SECOND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Tammenoms Bakker Juliet

    (Last) (First) (Middle)
    2740 SAND HILL ROAD, SECOND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Longitude Venture Partners II, L.P. ("LVPII") exercised warrants to purchase an aggregate of 629,032 shares of the Issuer's Class A common stock for $0.05 per share and paid the exercise price on a cashless basis, resulting in the Issuer withholding 7,739 shares of the Issuer's shares of Class A common stock subject to the warrant to pay the exercise price.
    2. The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.
    3. The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
    4. The warrant is immediately exercisable.
    /s/ Longitude Capital Partners II, LLC, By: /s/ Cristiana Blauth Oliveira, Authorized Signatory 02/03/2026
    /s/ Longitude Venture Partners II, L.P., By: /s/ Cristiana Blauth Oliveira, Authorized Signatory 02/03/2026
    /s/ Longitude Prime Partners, LLC, By: /s/ Cristiana Blauth Oliveira, Authorized Signatory 02/03/2026
    /s/ Longitude Prime Fund, L.P., By: /s/ Cristiana Blauth Oliveira, Authorized Signatory 02/03/2026
    /s/ Cristiana Blauth Oliveira, as attorney-in-fact for Patrick G. Enright 02/03/2026
    /s/ Cristiana Blauth Oliveira, as attorney-in-fact for Juliet Tammenoms Bakker 02/03/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RPID alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RPID

    DatePrice TargetRatingAnalyst
    7/28/2025$8.00Buy
    Lake Street
    2/12/2025$8.00Overweight
    KeyBanc Capital Markets
    8/16/2022Overweight → Neutral
    JP Morgan
    3/7/2022$11.00 → $10.00Equal-Weight
    Morgan Stanley
    2/15/2022$24.00 → $11.00Equal-Weight
    Morgan Stanley
    11/15/2021$26.00 → $24.00Equal-Weight
    Morgan Stanley
    8/9/2021Outperform
    Cowen
    8/9/2021$26.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $RPID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF OPERATING OFFICER Wilson John J. Addington sold $17,438 worth of shares (4,610 units at $3.78), decreasing direct ownership by 2% to 257,768 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    2/10/26 6:58:23 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CHIEF FINANCIAL OFFICER Wirtjes Sean M sold $22,798 worth of shares (6,027 units at $3.78), decreasing direct ownership by 1% to 483,928 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    2/10/26 6:54:52 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT AND CEO Spignesi Robert G. Jr. sold $48,570 worth of shares (12,840 units at $3.78), decreasing direct ownership by 1% to 962,097 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    2/10/26 6:52:52 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pei Melinda Litherland bought $20,364 worth of shares (20,000 units at $1.02), increasing direct ownership by 58% to 54,300 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    12/5/24 6:44:47 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Pei Melinda Litherland bought $20,999 worth of shares (20,000 units at $1.05), increasing direct ownership by 140% to 34,300 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    11/27/24 9:42:03 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Malloy Kirk bought $45,335 worth of shares (50,000 units at $0.91), increasing direct ownership by 350% to 64,300 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    8/9/24 8:36:24 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $RPID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

    Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period.Received record multi-system order in the fourth quarter from an existing Top 20 global biopharma customer to automate global manufacturing network.Full year 2025 total revenue expected to be approximately $33.6 million, representing growth of approximately 20% compared to the prior year. LEXINGTON, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and f

    1/13/26 4:15:00 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems to Present at 44th Annual J.P. Morgan Healthcare Conference

    LEXINGTON, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The Company is scheduled to present on Thursday, January 15, 2026, at 2:15 p.m. Eastern Time (11:15 a.m. Pacific Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be

    1/7/26 9:00:00 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance

    Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable revenue. Reports third quarter gross margin of 9%, representing a 70-basis point improvement compared to the third quarter of 2024.Announces record multi-system order from an existing Top 20 global biopharma customer to automate global manufacturing network. Raises full year 2025 total revenue guidance to at least $33.0 million, which assumes at least 27 Growth Direct system placements. LEXINGTON, Mas

    11/7/25 6:00:00 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Lake Street initiated coverage on Rapid Micro Biosystems with a new price target

    Lake Street initiated coverage of Rapid Micro Biosystems with a rating of Buy and set a new price target of $8.00

    7/28/25 8:29:57 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    KeyBanc Capital Markets initiated coverage on Rapid Micro Biosystems with a new price target

    KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00

    2/12/25 7:09:40 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems downgraded by JP Morgan

    JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral

    8/16/22 7:57:15 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    SEC Filings

    View All

    SEC Form 144 filed by Rapid Micro Biosystems Inc.

    144 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    2/9/26 4:33:38 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

    1/13/26 4:16:51 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Rapid Micro Biosystems Inc.

    10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

    11/7/25 5:06:51 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Leadership Updates

    Live Leadership Updates

    View All

    Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors

    LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company" or "Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Dr. Dafni Bika to the Company's Board of Directors (the "Board"). "We are extremely pleased to welcome Dr. Bika to our Board of Directors," said Robert Spignesi, President and Chief Executive Officer. "Dafni has more than 25 years of leadership experience in pharmaceutical development and manufacturing science and technology. She brings a wealth of knowledge an

    5/27/25 9:00:22 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors

    LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar

    7/18/23 5:20:56 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Announces the Appointment of Michael Wysocki as Senior Vice President, Sales and Marketing

    LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S

    5/4/23 4:30:10 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Financials

    Live finance-specific insights

    View All

    Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance

    Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable revenue. Reports third quarter gross margin of 9%, representing a 70-basis point improvement compared to the third quarter of 2024.Announces record multi-system order from an existing Top 20 global biopharma customer to automate global manufacturing network. Raises full year 2025 total revenue guidance to at least $33.0 million, which assumes at least 27 Growth Direct system placements. LEXINGTON, Mas

    11/7/25 6:00:00 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems to Announce Third Quarter 2025 Financial Results on November 7, 2025

    LEXINGTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2025 financial results prior to the market open on Friday, November 7, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, November 7, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for rep

    10/28/25 5:05:00 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results

    Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compared to the second quarter of 2024. Enters into five-year, $45 million term loan facility with $20 million funded at close. Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology c

    8/12/25 6:31:30 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    2/14/24 10:04:40 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    1/22/24 5:28:26 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    2/14/23 4:17:23 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials